ITPRIPL1 Regulators for CD3ε-Mediated Tumor Immune Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective methods to regulate immune responses and suppress tumors, as there is a lack of natural non-antibody proteins known to bind to the CD3ε extracellular domain, and existing treatments for immune-related diseases and tumors are limited in efficacy.
Innovation Solution
Utilizing ITPRIPL1 as a regulator through gene editing, RNA molecules, nucleic acid molecules, recombinant proteins, or antibodies to modulate its expression or function, specifically targeting CD3ε and NRP2, to regulate immune responses and suppress tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatment methods are used for immune-related diseases and tumors, then current treatments can be applied, but the efficacy is limited
Solution Approach 1:
The patent introduces ITPRIPL1 as a novel intermediary target that connects tumor cells with the immune system. By developing antibodies that specifically bind to ITPRIPL1, the invention creates a new mediator that enhances immune recognition of tumors without relying on existing treatment mechanisms, thereby improving both efficacy and treatment versatility
Solution Approach 2:
The ITPRIPL1-targeted antibody platform demonstrates multi-functionality by being applicable to various immune-related conditions including tumors, autoimmune diseases, and transplant rejection. This universal approach allows a single therapeutic strategy to address multiple disease types, expanding treatment options beyond disease-specific therapies
2Reliability
If ITPRIPL1 is used as a regulator to enhance immune responses, then tumor suppression and immune regulation are improved, but the complexity of the treatment approach increases
Solution Approach 1:
The patent extracts and isolates the specific extracellular domain of ITPRIPL1 as a discrete therapeutic target. By focusing on this specific region rather than attempting to modulate the entire ITPRIPL1 protein or multiple immune pathways simultaneously, the treatment approach is simplified while maintaining effective immune response regulation
Solution Approach 2:
The invention uses recombinant ITPRIPL1 proteins and antibody fragments that replicate the function of natural immune regulators. These copied molecular structures can be produced in large quantities with consistent properties, providing a simplified and scalable treatment approach compared to using complex biological extracts or multiple different therapeutic agents
Data Source
Figure 1(a)~1(c)
Figure 2(a)~2(d)
Figure 3(a)~3(d)
AI summary
Provided is a use of a regulator of ITPRIPL1 in the preparation of a drug that regulates immune responses or resists tumors, the regulator being used to increase or decrease the expression or function of the ITPRIPL1 gene or protein in an organism. Also provided is a pharmaceutical composition, which comprises the regulator used in the use. Also provided are an isolated ITPRIPL1 recombinant protein and an antibody that recognizes and binds to the ITPRIPL1. On the basis of the principle that an ITPRIPL1 protein binds to CD3ε and NRP2 receptors to regulate the functions of different immune cells, and then participates in the regulation of immune responses and a process of immune evasion of a tumor, it is confirmed that a regulator of ITPRIPL1 may be used to prepare a drug or a pharmaceutical composition, and may be applied to suppress tumors, autoimmune disease, transplant rejection, allergies and infections and other diseases.